One of the first tasks after the Lunar New Year for China’s National Health Commission (NHC) was to release a draft guideline on Feb. 26 to rein in a seemingly wild area of development in the country - cell and gene therapy.
The move was prompted by a string of clinical trials in which Chinese researchers stunned the world with gene-editing technology